[{"id":"963274c2-ef1a-43d9-bccd-99053c776187","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599634","created_at":"2023-06-02T17:05:43.963Z","updated_at":"2025-02-25T16:53:20.802Z","phase":"Phase 1","brief_title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","source_id_and_acronym":"NCT04599634","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 06/20/2024","study_completion_date":" 06/20/2024","last_update_posted":"2025-02-04"},{"id":"a17ffe57-fe51-4cfc-be1c-843d4dbb12e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00185692","created_at":"2021-01-18T00:37:49.022Z","updated_at":"2024-07-02T16:36:52.917Z","phase":"Phase 2","brief_title":"Allogeneic Transplantation From Related Haploidentical Donors","source_id_and_acronym":"NCT00185692","lead_sponsor":"Stanford University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporine • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2019-12-04"},{"id":"907330ac-d47a-48c8-8364-0da4c8218c56","acronym":"GRAAPH2014","url":"https://clinicaltrials.gov/study/NCT02611492","created_at":"2021-01-18T12:41:16.203Z","updated_at":"2024-07-02T16:36:54.402Z","phase":"Phase 3","brief_title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","source_id_and_acronym":"NCT02611492 - GRAAPH2014","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • vincristine • mercaptopurine delayed release (DR6MP) • mercaptopurine • methylprednisolone acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2019-10-21"},{"id":"f098b0c9-04d9-4c7d-8399-1bb7e2d2b40a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01093586","created_at":"2021-01-18T04:19:20.928Z","updated_at":"2025-02-25T16:23:22.361Z","phase":"Phase 2","brief_title":"Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT01093586","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" KMT2A • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2019-01-23"},{"id":"ceca6fdb-fd86-42d6-9240-af9a922fc7d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00309907","created_at":"2021-01-18T01:03:56.850Z","updated_at":"2025-02-25T16:22:15.395Z","phase":"Phase 2","brief_title":"Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant","source_id_and_acronym":"NCT00309907","lead_sponsor":"Children's Oncology Group","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methylprednisolone acetate"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":" Completion: 09/01/2011","study_completion_date":" 09/01/2011","last_update_posted":"2017-09-29"}]